Newsletter Signup | Join Community
Checkpoint inhibitor Inlyta combo now FDA approved - likely to become new standard treatment for renal cell cancer
Update on treatment progress, the new role of precision immunotherapy and ALL the approved treatments for kidney cancer.
First-Line Inlyta Active in Metastatic Kidney Cancer
Opdivo® approved by US FDA for treatment of advanced renal cell cancer.
Inlyta Approved for Advanced Kidney Cancer.
Oral Precision Cancer Medicine Votrient Improves Progression-free Survival in Advanced Kidney Cancer.
Long-Term Survival of Patients with Renal Cell Cancer After High-Dose Continuous Infusion of Interleukin-2
Updated Results Confirm Survival Benefit of Nexavar® in Renal Cell Carcinoma
Dr. Janice Dutcher (NY), Dr. Keith Flaherty (Penn) Dr. David I. Quinn (USC) discuss kidney cancer.
Bevacizumab Delays Cancer Progression in Metastatic Renal Cell Cancer
Laparoscopic radical nephrectomy is now a standard treatment and associated with reduced complications.
UCLA doctors report that partial nephrectomy as effective as nephrectomy in patients with localized renal cell cancer.
Mortality from Some Cancer Surgeries Reduced in Large-Volume Hospitals
Stay Current With Renal Cancer Treatment Advances & Connect with Others
Dana Farber researchers work to develop NeoVax vaccine for the treatment of renal cell cancer.
ENPP3 targeted therapy is undergoing clinical trial evaluation for advanced renal cell cancer.
Radical nephrectomy combined with imminotherapy improves survival in individuals with metastatic kidney cancer.
Updated clinical trial results reveal Tivozanib superior to Nexavar and headed to the FDA for US approval.
FDA Approves Torisel™ and NCCN Adds to Standard Treatment Guidelines for Kidney Cancer
FDA Grants Breakthrough Therapy Designation to LENVIMA™ for the Potential Treatment of Metastatic Renal Cell Carcinoma
Siblings of Kidney Cancer Patients at Increased Risk for the Disease.
Cancer Connect - Treatment of Recurrent Kidney Cancer
Radiofrequency Ablation Promising for Small Renal Tumors
The FDA granted approval to nivolumab (Opdivo) for patients with renal cell carcinoma.
Sterotactic Radiosurgery Alone Is Preferred Treatment for Newly Diagnosed Brain Metastases
Wilms’ Tumor Prognosis Influenced by Chromosomal Changes
Impressive Survival After Treatment of Kidney Cancer with Tarceva® and Avastin®
With advances in personalized medicine, the look and feel of cancer treatment may change dramatically.
FDA Grants Approval to Cabometyx for First-Line Treatment of Advanced Renal Cell Carcinoma
Vaccine Improves Progression-Free Survival in Kidney Cancer.
Genetic Testing Predicts Risk of Relapse in Wilms’ Tumor
Targeted Drugs Produce Complete Responses in Some Patients with Metastatic Kidney Cancer
Partial Nephrectomy is Associated with Improved Survival in Early Stage Kidney Cancer.
Adjuvant Interferon not Effective for Patients with Locally Advanced Renal Cell Carcinoma
Sorafenib Improves Outcome of Metastatic Renal Cell Carcinoma
Predicting Better Survival for Kidney Cancer Patients After Allogeneic Stem Cell Transplant
Axitinib Provides Activity in Kidney Cancer
Biological Therapy May Afford Better Survival Time than Chemotherapy for Metastatic Renal Cell Cancer
Avastin® Plus Tarceva® Provides Impressive Survival in Metastatic Renal Cell Carcinoma.
Nexavar® plus Interferon Effective in Metastatic Kidney Cancer
VEGF Inhibitors Require Appropriate Hypertension Assessment, and Management
More Frequent Use of Partial Nephrectomy May Benefit Kidney Cancer Patients
Nephron-Sparing Surgery Effective in Early-Stage Renal Cancer
IPM Chemotherapy Produces Responses in Renal Cell Cancer that Stops Responding to Immunotherapy
Immune Therapy Promising for Advanced Renal Cell Cancer.
Thalidomide Produces Responses in Advanced Renal Cell Cancer
The Biologic Therapy Is more Effective for Treatment of Renal Cancer.
Regular Use of Nonaspirin NSAIDs May Increase Kidney Cancer Risk
Inhaled Interleukin-2 May Control Cancer That Has Spread to Lungs in Patients with Kidney Cancer
Sorafenib® May be Available for Patients with Advanced Renal Cell Carcinoma
Bone Outcomes Not Improved when Zometa® is Combined with Thalidomide and Interferon-y
Less Extensive Surgery May Benefit Younger Patients with Small Renal Tumors
Gene Expression of Kidney Cancers May Aid in Diagnosis.
Nexavar® Improves Patient Outcomes Without Compromising Quality of Life
Avastin® and Reduced Doses of Interferon Effective and Tolerable in Advanced Kidney Cancer.
Afinitor® Approved for Advanced Kidney Cancer
Interferon Does Not Improve Outcomes of Stage II-III Kidney Cancer
Axitinib Improves Outcomes with Metastatic Kidney Cancer
Removal of the Kidney May Prolong Survival in Persons with Metastatic Renal Cell Carcinoma
Long-Term Interferon Effective for Metastatic Kidney Cancer
PD-1 Targeted Immune Therapy Shows Promising Activity
Metastatic Renal Cell Carcinoma: Successful Treatment with an Allogeneic Blood Stem Cell Transplant
Randomized Comparison of Interleukin-2, Alfa Interferon or Both for the Treatment of Patients with Metastatic Renal Cell
Assessing Recurrence Risk in Kidney Cancer.
A Four Drug Combination of Retinoic Acid, Interferon, Interleukin-2 and Chemotherapy was More Effective
Thalidomide May Increase Effectiveness of Proleukin® in Advanced Kidney Cancer
Immune Cells May Improve Survival in Advanced Kidney Cancer.
Radical Nephrectomy Prior to Interferon Improves Survival for Metastatic Renal Cell Cancer
Outpatient Interleukin-2-Based Combination Therapy is as Effective as High-Dose Interleukin-2 Treatment
Long-Term, Low-Dose Interleukin and Interferon for Advanced Renal Cancer
Inhaled Interleukin-2 Therapy is Effective Palliation for Patients with Metastatic Renal Cell Cancer in the Lung
The probability of a person developing cancer depends on both genetic and non-genetic factors.
Radical Nephrectomy Increases Risk of Chronic Kidney Disease
Evaluation of Anti-Epidermal Growth Factor Receptor Antibody C225 Alone in Patients Produces Some Responses
Avastin™ Delays Progression of Metastatic Kidney Cancer
Blood Pressure Monitoring Recommended for Kidney Cancer Patients Treated with Nexavar®
Nexavar® Has Significant Activity in Metastatic Renal Cell Carcinoma
Avastin® Improves Progression-free Survival in Metastatic Kidney Cancer
Preoperative Chemotherapy for Wilms’ Tumor Recommended
High-Dose Interleukin-2 Benefits Some Patients with Metastatic Kidney Cancer
Organ Transplant Recipients Have Increased Cancer Risk
Chronic Hepatitis C Infection May Increase Risk for Developing Renal Cell Carcinoma
Addition of Low-dose Interferon Alfa to Nexavar® Does Not Improve Kidney Cancer Outcomes
Cryoablation Effective for Renal Cancer.
Regression of Advanced Kidney Cancer Achieved Following Donor Stem Cell Infusions.
Surgical Resection of Metastatic Renal Cell Cancer can be Curative in Some Patients.
High Dose Interleukin-2 Regimen May Be Superior to Other Regimens for Treatment of Metastatic Renal Cell Cancer
Consumption of Fatty Fish May Reduce Risk of Kidney Cancer
Tarceva™ Plus Avastin® Highly Active in Advanced Kidney Cancer
Performance Status Indicative of Need for Bone Scan in Kidney Cancer
Panitumumab Targeted Therapy Provides Anticancer Activity in Patients with Advanced Colorectal Cancer.
Targeted Therapy and Renal Cell Carcinoma: Are We Making Progress?
Cardiac Toxicity in Patients with Metastatic Renal Cell Carcinoma Receiving Tyrosine Kinase Inhibitors
Everolimus Improves Progression-Free Survival in Kidney Cancer
Neovastat Doubles Survival Time for Patients with Advanced Renal Cancer
Nexavar® Improves Progression-free Survival in Advanced Kidney Cancer
Addition of Erbitux® to XELOX Reduces Cancer Progression as First-line Therapy in Metastatic Colorectal Cancer
More Evidence that Surgery Prior to Interferon Improves Survival in Advanced Renal Cell Carcinoma
Drinking More Fluids May Reduce the Risk for Bladder Cancer in Men
FDA Approves Torisel™ For Kidney Cancer
New Treatments Improve Outcomes for Metastatic Kidney Cancer
Avastin® Approved for Kidney Cancer
Adhesive Instead of Stitches May Reduce Surgery Complications in Kidney Cancer
High Levels of Survivin Associated with Poorer Survival in Renal Cell Carcinoma
Revlimid® Has Activity in Metastatic Renal Cell Carcinoma
Protein Linked with Kidney Cancer Prognosis.
Avastin® Improves Survival in Kidney Cancer
Addition of Gliadel® Wafer to Surgery and Radiation Effective for Brain Metastasis
Update on the Management of Genitourinary Malignancies.
Urologic and Colorectal Cancer Rates Linked in New Study
Profile of Katherine Phillion who was diagnosed with kidney cancer as a young adult at age 32.
The Importance of Utilizing Multiple Biological Pathways to Predict Tumor Behavior in Prostate and Renal Cancers
Thalidomide and IL-2 Effective for Metastatic Renal Cell Carcinoma
Radiofrequency Ablation Effective in Small Kidney Cancers
The treatment options for patients with metastatic renal cell cancer remain limited and unsatisfactory.
Worth a Look: It’s Kidney Cancer Awareness Month.
Clinical Study Evaluating Dalantercept in Combination with Axitinib Now Enrolling Advanced RCC Patients Nationwide
Partial Nephrectomy for Renal Cell Cancer Can Achieve Long-Term Tumor Control
Radiofrequency Ablation Can Effectively Treat Patients with Small Cancers of the Kidney.
Nexavar® Approved for Treatment of Advanced Kidney Cancer
Study Continues to Suggest Benefit of Nexavar® in the Treatment of Advanced Kidney Cancer
Checkpoint Inhibitors Improve Outcomes of Renal Cell Cancer
Nexavar® Effective in Elderly Patients with Kidney Cancer.
Radiofrequency Ablation an Effective Alternative to Surgery in Renal Cell Cancer
For patients diagnosed with for renal cell cancer (RCC), or kidney cancer, surgery is often the mainstay of treatment.
Sunitinib Promising for Metastatic Renal Cell Carcinoma
Afinitor® Approved for Treatment of Advanced Renal Cell Carcinoma After Failure of Sutent® or Nexavar®
Surgery Can Lengthen Survival of Metastatic Kidney Cancer Patients Treated with Targeted Therapies, Study Finds
Novel Agent Appears Promising for Treatment of Some Cancers
Has anyone had their kidney cancer removed by laproscope? Doctor says recovery will be much quicker.…